Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioventus Inc.
Minute Insight: Bioventus Completes CartiHeal Acquisition Following Agili-C Approval
Bioventus exercised a “call option” to acquire CartiHeal for about $315m, plus up to $135m in milestones. The US FDA recently approved CartiHeal’s Agili-C implant to treat knee joint surface lesions.
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
AAOS 2021: Digital Tools In Surgical Ecosystem, Software-Enabled Tech, Robots, Wearables, Sensors
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
Market Brief: Orthobiologics Market Will See Modest Growth By 2024, Stimulated By Growth Factors
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
- Implantable Devices
- Large Molecule
- Other Names / Subsidiaries
- Bioventus Inc.
- Bioventus Coöperatief U.A.
- BioStructures LLC
- Bioness, Inc.
- CartiHeal Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.